UK 'value-based' pricing talks start next month
This article was originally published in Scrip
Negotiations on the UK's new value-based pricing system are set to begin next month, a joint statement from the Association of the British Pharmaceutical Industry and England's Department of Health has confirmed. The industry association and the government will thrash out the landscape for drugs already on the market. They will also discuss whether value-based pricing will encompass oncology drugs that failed to pass muster with NICE, the health technology appraisal body for England and Wales. At present NICE-rejected oncology drugs can get a second chance for funding in England through the Cancer Drugs Fund.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.